$2.20
2.65% yesterday
Nasdaq, Nov 03, 10:08 pm CET
ISIN
US75955J2042
Symbol
RLMD

Relmada Therapeutics Inc Stock price

$2.20
-0.12 5.17% 1M
+1.82 474.11% 6M
+1.68 323.08% YTD
-1.22 35.67% 1Y
-4.50 67.16% 3Y
-29.27 93.01% 5Y
-11.00 83.33% 10Y
-57.80 96.33% 20Y
Nasdaq, Closing price Mon, Nov 03 2025
-0.06 2.65%
ISIN
US75955J2042
Symbol
RLMD
Industry

Key metrics

Basic
Market capitalization
$73.0m
Enterprise Value
$52.4m
Net debt
positive
Cash
$20.6m
Shares outstanding
33.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
4.6
Financial Health
Equity Ratio
77.5%
Return on Equity
-225.2%
ROCE
-441.0%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
- | $-105.6m
EBIT
$-70.5m | $-61.8m
Net Income
$-68.1m | $-65.3m
Free Cash Flow
$-50.2m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
- | -
EBIT
22.9% | 26.3%
Net Income
21.7% | 18.3%
Free Cash Flow
-4.9%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-2.1
FCF per Share
$-1.5
Short interest
1.7%
Employees
17
Rev per Employee
$0.0
Show more

Is Relmada Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,031 stocks worldwide.

Relmada Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Relmada Therapeutics Inc forecast:

4x Hold
57%
3x Sell
43%

Analyst Opinions

7 Analysts have issued a Relmada Therapeutics Inc forecast:

Hold
57%
Sell
43%

Financial data from Relmada Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 34 34
20% 20%
-
- Research and Development Expense 37 37
25% 25%
-
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -71 -71
23% 23%
-
Net Profit -68 -68
22% 22%
-

In millions USD.

Don't miss a Thing! We will send you all news about Relmada Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Relmada Therapeutics Inc Stock News

Neutral
GlobeNewsWire
about one hour ago
CORAL GABLES, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system indications, today announced the pricing of its underwritten offering of 40,142,000 shares of its common stock and, in lieu of common stock to certain investors, ...
Neutral
GlobeNewsWire
about one hour ago
Announces NDV-01 9-Month Follow-up Safety and Efficacy Data in NMIBC FDA feedback supports 2 potential registrational trials – 1) a registrational trial in 2nd line refractory BCG-unresponsive NMIBC, and 2) a randomized controlled trial in intermediate-risk NMIBC. FDA Feedback also confirms no additional non-clinical studies are required.
Neutral
GlobeNewsWire
28 days ago
Dr. Kates' experience as chair of the landmark Phase 3 BRIDGE bladder cancer trial and dedication to patient care will be invaluable to the NDV-01 Phase 3 program
More Relmada Therapeutics Inc News

Company Profile

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company. It engages in the development of d-methadone receptor antagonist, which is a chemical entity that addresses areas of high unmet medical need in the treatment of central nervous system diseases and other disorders. The company was founded on May 31, 2012 and is headquartered in New York, NY.

Head office United States
CEO Sergio Traversa
Employees 17
Founded 2012
Website www.relmada.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today